BioCentury | Sep 26, 2018
Distillery Therapeutics

Neurology

INDICATION: Leukodystrophy Cell culture, worm and mouse studies suggest inhibiting HDAC6 and other HDACs could help treat Cockayne syndrome, a leukodystrophy caused by ERCC6 mutations that is associated with defects in autophagy, neurogenesis and neuronal...
BioCentury | Oct 13, 2016
Strategy

Exosomes in the zone

Mark Zipkin, Staff Writer Having had a slow on-ramp to recognition as more than cellular garbage bags, exosomes are gaining status as a potentially transformational technology, with utility in both diagnostics and therapeutics. But the...
BioCentury | Sep 1, 2016
Distillery Techniques

Techniques: Variants in a panel of 72 genes as risk markers for sarcoma

...and variants in ataxia telangiectasia mutated (ATM) , breast cancer 2 early onset (BRCA2) , excision repair cross-complementation group 2 (ERCC2)...
BioCentury | Mar 17, 2016
Distillery Therapeutics

Therapeutics: Brain-derived neurotrophic factor (BDNF); neurotrophic tyrosine kinase receptor 2 (TrkB; NTRK2); excision repair cross-complementation group 6 (ER

Neurology INDICATION: Leukodystrophy Patient sample and cell studies suggest BDNF , BDNF mimetics or other agonists of its receptor, TrkB , could help treat Cockayne syndrome, a leukodystrophy caused by ERCC6 mutations that is associated with defects...
BioCentury | Dec 10, 2015
Product R&D

Stem and deliver

Exosomes, once considered cellular debris, are gaining a name in cancer as biopsy-free diagnostic agents, and in drug delivery for their ability to enter cells in a targeted manner. Now, Capricor Therapeutics Inc. wants to...
BioCentury | Oct 1, 2015
Tools & Techniques

NCATS's extracellular revolution

Two years into its five-year run, a $117.5 million NIH-funded consortium established to look for biomarkers and therapies stemming from extracellular RNA (exRNA) research is now moving into its testing and validation phase, after completing...
BioCentury | Sep 4, 2014
Distillery Techniques

Technology: Markers

...Approach Summary Licensing status Publication and contact information Markers Excision repair cross-complementation group 2 (ERCC2) mutations as a predictive marker of...
...sensitivity in urothelial carcinomas Studies in patient samples and cell culture suggest loss-of-function mutations in ERCC2...
...patient-derived, ERCC2-deficient cell line, overexpression of ERCC2 decreased cisplatin sensitivity compared with overexpression of mutant ERCC2...
BioCentury | Feb 10, 2011
Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer Excision repair cross-complementing group 3 (ERCC3; XPB) In vitro studies suggest that the XPB inhibitor triptolide could help treat cancer. In HeLa cells, triptolide...
BioCentury | Jul 17, 2008
Distillery Therapeutics

This Week in Therapeutics

This week in therapeutics Indication Target/marker/ pathway Summary Licensing status Publication and contact information Cancer Ovarian cancer Excision repair cross-complementing rodent repair deficiency, complementation group 5 (ERCC5) A genome-wide association study suggests that ERCC5 could...
BioCentury | Jun 30, 2008
Clinical News

Satraplatin: Phase II started

GPC began an open-label, U.S. Phase II trial to evaluate oral satraplatin in combination with prednisone in up to 66 patients previously treated with docetaxel. GPC licensed Orplatna from Spectrum in 2002, while Celgene has...
Items per page:
1 - 10 of 13